NurExone Biologic For Profit
New approach to Spinal Cord Injury treatment based on view that intranasal exosome administration offers alternative to cell transplantation
Founded Date:
2020-01-01
Headquarters:
Haifa, Hefa, Israel
Technology:
Stem cells
Employee Number:
11-50
Industry:
Regenerative Medicine
Estimated Revenue:
$5.2 billion dollars